Abstract:e23123 Background: Pleural carcinosis caused by tumors of the chest (e.g., lung and breast cancer) or elsewhere in the body (e.g., ovarian carcinoma) that metastasize to the visceral and/or parietal pleura. Recurrent malignant pleural effusion due to pleural carcinosis is one of the most common findings in oncology. The aim of the study was to identify a miRNA signature associated with clinicians’ prescription of patients with MPE. Methods: We used qRT-PCR assay to evaluate a wide range miRNAs (1920 miRNAs) signature measured from pleural effusion between patients with cancer and healthy controls. From the data of our previous studies we selected a panel of 96 miRNAs related to malignant pleural effusion. Data were compared by three classification methods software for statistics and modeling. We used a first set of 77 pleural effusion samples as training group, including 27 patients affected by Lung Adenocarcinomas (LAC), 9 with other lung cancer, 17 with other tumors and 24 inflammatory patients as negative controls. Moreover, we used more 64 pleural effusion samples for double-blind predictive study. Data analysis was performed using a machine learning approach of a Support Vector Machine classifier with a Student's t-test feature selection procedure. Results: We identified a panel of ten miRNAs with optimum classification performance. The combination of these 10-miRNAs alone could discriminate MPE cases from negative controls with an AUC of 0.969 (accuracy = 93.5%; specificity = 91.7%). The selected panel of another 10-miRNAs could separate lung cancer cases from negative controls with an AUC of 0.973 (accuracy = 94.8%; specificity = 95.8%), and a small panel of 4-miRNAs could good discriminate LAC cases from negative controls with an AUC of 0.946 (accuracy 88.9%; specificity = 100%). The accuracy rate of the double-blind predictive sensitivity value was 90.9% and specificity value was 95.8% for MPE patients with lung cancer of miRNA signature. Conclusions: Our miRNAs profile may serve as a new biomarker for MPE diagnosis. Otherwise, we identified a 10-miRNAs signature for MPE patients with lung cancer and a 4-miRNAs for MPE patients with lung adenocarcinoma.

Determination of Ki-67 Expression and Its Significance in Cell Smears of Pleural Effusion and Ascites using Thin-layer Cytology Test

Cytology Cell Blocks from Malignant Pleural Effusion Are Good Candidates for PD-L1 Detection in Advanced NSCLC Compared with Matched Histology Samples

Values of immunocytochemical and quantitative morphometric analyses in cytological differential diagnosis of pleural and peritoneal effusion

The study of pleural lavage cytology for lung cancer

The expression levels of VEGF and ICAM-1 in pleural effusion

Immunohistochemical detection and molecular pathological examination of 142 cases of malignant pleural effusion

Diagnostic Value of Thin-Cytological Test and Routine Cytological Detection for Patients

Combined Detection of Carcinoembryonic Antigen and C-reactive Protein in Identifying Benign and Malignant Pleural Effusion

Application value of combined detection of exfoliative cytology,DNA heteroploid analysis and serum tumor marker in malignant pleural/ascitic fluid

The Diagnostic Significance of the Detection of Cytokeratin 19 Mrna by Quantitative RT-PCR in Benign and Malignant Pleural Effusions

Ki-67 Antigen's Expression in Benign and Malignant Neoplasms of Colorectum and Its Clinical Significance

Clinical Significance of Combined Detection of CEA, CYFRA21-1,CA19-9 and Fer in Differential Diagnosis of Benign Pleural Effusion and Malignant Pleural Effusion

Genome-wide Microrna Expression Profiling in Malignant Pleural Effusion to Identify a Ten-Microrna Signature.

The study of cellular proliferous ki-67 antigen in screening cervical preinvasive lesion and cervical carcinoma

Pleural fluid analysis of lung cancer vs benign inflammatory disease patients

Diagnostic Accuracy of Cancer in Pleural Effusion: A Combination Serum Tumor Markers and Cytology

Clinical Value of Qualitative Determination of C-Reactive Protein in the Differential Diagnosis of Benign and Malignant Pleural Effusions or Ascites

Diagnostic value of combined determination of mdikine with CEA level in differentiating malignant pleural effusion from tuberculous pleural effusion

Expression and significance of MOC-31 and calretinin in pleural fluid of patients with lung cancer.

Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas

Application of Three Tumor Markers United Detection in Differentiating Benign and Malignant Pleural Effusion